Ruxolitinib: A review of its use in patients with myelofibrosis

Drugs

Volumn 75, Issue 3, 2015, Pages 297-308

  Plosker, Greg L ^a  

^a Springer   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; ARTICLE; CONSTIPATION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; DYSPNEA; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FATIGUE; FEVER; FLATULENCE; FOLLOW UP; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; INSOMNIA; JAPANESE (PEOPLE); LIMB PAIN; LONG TERM CARE; MYELOFIBROSIS; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS; SPLENOMEGALY; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; ENZYMOLOGY; PRIMARY MYELOFIBROSIS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JANUS KINASE 1; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PYRAZOLES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84925507072     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0351-8     Document Type: Article

References (68)

1. Gregory SA, Mesa RA, Hoffman R, et al. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Clin Adv Hematol Oncol. 2011;9(9 Suppl 22):1-16.
2. Mughal TI, Vaddi K, Sarlis NJ, et al. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89-101.
3. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
4. Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595-600.
5. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-901.
6. Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc. 2012;87(1):25-33.
7. Verstovsek S. Changing myelofibrosis's natural course at last. Blood. 2014;123(12):1776-7.
8. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26):4399-413.
9. Santos FP, Verstovsek S. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? Anticancer Agents Med Chem. 2012;12(9):1098-109.
10. Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 2010;3(3):323-37.
11. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-82.
12. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-405.
13. Yang LPH, Keating GM. Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012;72(16):2117-27.
14. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-17.
15. Jakafi (ruxolitinib) tablets for oral use: US prescribing information. 2014. http://www.incyte.com/sites/default/files/Jakafi-PI-0.pdf. Accessed 24 Dec 2014.
16. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-27.
17. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807 [plus supplementary appendix].
18. Vannucchi A, Kiladjian JJ, Gisslinger H, et al. Reductions in Jak2v617f allele burden with ruxolitinib treatment in Comfort-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT) [abstract no. 0373]. In: 17th Congress of the European Haematology Association. 2012.
19. Quintas-Cardama A, Kantarjian H, Cortes J, et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127-40.
20. European Medicines Agency. Jakavi tablets: summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002464/WC500133223.pdf. Accessed 30 Sep 2014.
21. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51(12):1644-54.
22. Shilling AD, Nedza FM, Emm T, et al. Metabolism, excretion, and pharmacokinetics of [14C] INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug Metab Dispos. 2010;38(11):2023-31.
23. Chen X, Williams WV, Sandor V, et al. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol. 2013;53(7):721-30.
24. Ogama Y, Mineyama T, Yamamoto A, et al. A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. Int J Hematol. 2013;97(3):351-9.
25. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012;52(6):809-18.
26. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood. 2012;120(6):1202-9.
27. Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy [abstract no. 4055]. Blood. 2013;122(21).
28. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865-71.
29. Verstovsek S, Mesa RA, Gotlib J, et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 3-year update from COMFORT-I [abstract no. 396]. Blood. 2013;122(21).
30. Verstovsek S, Mesa RA, Gotlib J, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol. 2013;161(4):508-16.
31. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31(10):1285-92.
32. Mesa RA, Verstovsek S, Gupta V, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I [abstract no. 1733]. Blood. 2012;120(21).
33. Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J Hematol Oncol. 2013;6(1).
34. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-98 [plus supplementary appendix].
35. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-53.
36. Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123(12):1833-5.
37. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365(15):1455-7.
38. Guglielmelli P, Biamonte F, Rotunno G, et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood. 2014;123(14):2157-60.
39. Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013;162(2):229-39.
40. Harrison C, Kiladjian JJ, Gisslinger H, et al. Multivariate analysis of the association of cytokine levels and reductions in spleen size in COMFORT-II, a phase 3 study comparing ruxolitinib to best available therapy (BAT) [abstract no. P269]. In: 18th Congress of the European Haematology Association. 2013.
41. Harrison C, Kiladjian JJ, Gisslinger H, et al. Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase 3 study comparing ruxolitinib to best available therapy (BAT) [abstract no. 0379]. In: 17th Congress of the European Haematology Association. 2012.
42. Squires M, Harrison CN, Barosi G, et al. The relationship between cytokine levels and symptoms in patients (pts) with myelofibrosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best available therapy (BAT) [abstract no. 4070]. Blood. 2013;122(21).
43. Vannucchi AM, Hagop K, Kiladjian JJ, et al. A pooled overall survival analysis of the COMFORT studies: 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis [abstract no. 2820]. Blood. 2013;122(21).
44. Jabbour E, Kantarjian HM, Ning J, et al. Prognostic factors for outcome in patients (pts) with myelofibrosis (MF) treated with ruxolitinib (Rux) [abstract no. 4050]. Blood. 2013;122(21).
45. Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2014;99(2):292-8.
46. Verstovsek S, Kiladjian JJ, Mesa RA, et al. Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials [abstract no. 2847]. Blood. 2012;120(21).
47. Jung CW, Shih LY, Xiao Z, et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymphoma. 2014:1-22.
48. Oritani K, Okamoto S, Tauchi T, et al. Efficacy and safety of ruxolitinib in Japanese patients with myelofibrosis (MF) [abstract no. OS-2-49]. In: 76th Annual Meeting of the Japanese Society of Hematology. 2014.
49. Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6:81.
50. Andreoli A, Rey J, Dauriac C, et al. Ruxolitinib therapy in myelofibrosis: Analysis of 241 patients treated in compassionate use (French "ATU" program) by the French intergroup of myeloproliferative neoplasms (FIM) [abstract no. 2841]. Blood. 2012;120(21).
51. Alzate MA, Osorio MJM, Barreyro P, et al. Ruxolitinib in myelofibrosis (MF) patients through compassionate use program (CUP). Argentinian experience [abstract no. 5247]. Blood. 2013;122(21).
52. Tabarroki A, Lindner D, Visconte V, et al. Modified dose escalation of ruxolitinib: a feasible therapeutic approach in the management of myelofibrosis [abstract no. 1586]. Blood. 2013;122(21).
53. Harrison CN, Clark RE, Chacko J, et al. Response to ruxolitinib in patients with intermediate-1, intermediate-2 and high-risk myelofibrosis: interim results of the UK Robust Trial [abstract no. 2826]. Blood. 2013;122(21).
54. Galli S, McLornan D, Harrison C. Safety evaluation of ruxolitinib for treating myelofibrosis. Expert Opin Drug Saf. 2014;13(7):967-76.
55. Verstovsek S, Gotlib J, Gupta V, et al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013;7:13-21.
56. Al-Ali HK, Stalbovskaya V, Gopalakrishna P, et al. Ruxolitinib overcomes the adverse prognostic effect of anemia in patients with myelofibrosis (MF) [abstract] In: 56th American Society of Hematology Annual Meeting and Exposition. 2014.
57. Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28(1):225-7.
58. Tong LX, Jackson J, Kerstetter J, et al. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol. 2014;70(3):e59-60.
59. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1, 2 inhibitor. Chest. 2013;143(5):1478-9.
60. Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369(7):681-3.
61. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188-91.
62. Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17):2635-42.
63. Harrison CN, Bennett M. Orphan drugs for myelofibrosis. Expert Opin Orphan Drugs. 2014;2(4):391-405.
64. Qureshi MR, MacLean C, McMullin MF, et al. Management of myelofibrosis: a survey of current practice in the United Kingdom. J Clin Pathol. 2012;65(12):1124-7.
65. Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J. 2012;2(3):e59.
66. Mascarenhas J. Rationale for combination therapy in myelofibrosis. Best Pract Res Clin Haematol. 2014;27(2):197-208.
67. Stubig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. Leukemia. 2014;28(8):1736-8.
68. Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2):179-84.